Sublingual immunotherapy efficacy of dermatophagoides farinae vaccine in a Murine asthma model

International Archives of Allergy and Immunology

Volumn 152, Issue 1, 2010, Pages 41-48

  Yu, Hai Qiong ^a,b,c   Li, Xiang Hui ^a,c   Guo, Hua ^a,d   Liu, Zhi Gang ^a   Ran, Pei Xin ^c   Ji, Kun Mei ^a   Wang, Jun ^a  

^a Shenzhen University School of Medicine   (China)

^b Shenzhen Futian People Hospital   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d NANCHANG UNIVERSITY   (China)

Author keywords

Allergen specific immunotherapy; Dermatophagoides farinae; Murine asthma model; Regulatory T cells; Sublingual vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; DERMATOPHAGOIDES FARINAE VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 4; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; BAGG ALBINO MOUSE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DERMATOPHAGOIDES FARINAE; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHIL; FEMALE; IMMUNITY; IMMUNOTHERAPY; LOW DRUG DOSE; LUNG LAVAGE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; MUCUS SECRETION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; SPLEEN CELL; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TH2 CELL; TREATMENT DURATION;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; DERMATOPHAGOIDES FARINAE; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYPERSENSITIVITY; MICE; MICE, INBRED BALB C; TH1 CELLS; TREATMENT OUTCOME; VACCINES;

EID: 70450193502     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260082     Document Type: Article

References (24)

1. Bousquet J, Lockey R, Malling HJ, et al.: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
2. Verhagen J, Taylor A, Blaser K, et al.: T regulatory cells in allergen-specific immunotherapy. Int Rev Immunol 2005; 24: 533-548.
3. Noon L: Prophylactic inoculation against hay fever. Lancet 1911;1:1572-1573.
4. Moreno C, Cuesta-Herranz J, Fernandez- Tavora L, et al.: Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004; 34: 527-531.
5. Moingeon P, Batard T, Fadel R, et al.: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61: 151-165.
6. Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of longterm sublingual immunotherapy in asthmatic children sensitized to mites: a doubleblind, placebo-controlled study. Allergy 2000; 55: 842-849.
7. Frew AJ: Sublingual immunotherapy. N Engl J Med 2008; 358: 2259-2264.
8. Nelson HS: The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 2000; 106: 41-45.
9. Malling H-J, Abreu-Nogueira J, Alvarez- Cuesta E, et al.: Local immunotherapy. EAACI position paper. Allergy 1998; 53: 933-944.
10. Joo-Hye Song, Nguyen HH, Cuburu N, et al.: Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA 2008; 105: 1644-1649.
11. Underwood S, Foster M, Raeburn D, et al.: Time-course of antigen-induced airway inflammation in the guinea pig and its relationship to airway hyperresponsiveness. Eur Respir J 1995; 8: 2104-2113.
12. Pearce N, Aït-Khaled N, Beasley R, et al.: Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758-766.
13. Swain SL, Weinberg AD, English M, et al.: IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145: 3796-3806.
14. Brusselle GG, Kips JC, Tavernier JH, et al.: Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy 1994; 24: 73-80.
15. Bohle B, Kinaciyan T, Gerstmayr M: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific Tcell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120: 707-713.
16. Miyara M, Wing K, Sakaguchi S: Mechanisms of allergic diseases: therapeutic approaches to allergy and autoimmunity based on Foxp3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 2009; 123: 749-755.
17. Bufe A, Ziegler-Kirbach E, Stoeckmann E, et al.: Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo- controlled study. Allergy 2004; 59: 498-504.
18. Marcucci F, Sensi L, Di Cara G, et al.: Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60: 952-956.
19. O'Brien RM, Byron KA, Varigos GA, Thomas WR: House dust mite immunotherapy results in a decrease in Der p 2-specific IFN- and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy 1997; 27: 46-51.
20. Akdis CA, Barlan IB, Bahceciler N, Akdis M: Immunological mechanism of sublingual immunotherapy. Allergy 2006; 61: 11-14.
21. Akdis M, Blaser K, Akdis CA: T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005; 116: 961-968.
22. Fontenot JD, Gavin MA , Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336.
23. Ling EM, Smith T, Nguyen XD, et al.: Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-615.
24. Becker JC, Czerny C, Bröcker E-B: Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 1994; 6: 1605-1612.